Cite

HARVARD Citation

    Foo, J. et al. (n.d.). 220 Cost per response for abatacept versus adalimumab in patients with seropositive erosive, early rheumatoid arthritis in the United States, Germany, Spain and Canada. Rheumatology. p. . [Online]. 
  
Back to record